Prostate Cancer

The report suggests that high-resolution micro-ultrasound could help identify clinically significant lesions that would be missed with conventional MRI.

The importance of identifying rare pathogenic mutations and genetic risk score among patients was explored in this new analysis, with goals that included reducing mortality and early disease detection.

A meta-analysis supported that Black men have similar or better prostate cancer outcomes compared with White men when health care access is equal and treatment is standardized for all patients.

Following the release of its 2023 report on cancer statistics, the American Cancer Society announced a new initiative to improve prostate cancer outcomes and reduce disparities.

William Oh, MD, chief medical officer at Sema4 and a clinical professor of medicine at Mount Sinai, discusses Prostate Cancer Awareness Month and possible reasons for disparities in diagnoses and mortality in prostate cancer.

Darolutamide, sold as Nubeqa, is an androgen receptor inhibitor, which works to limit prostate cell growth by preventing the binding of hormones, or androgens, to proteins known as androgen receptors.

Closing out their discussion on cardiovascular disease in prostate cancer, experts share their hopes for future evolution of the treatment landscape.

Shared insight on the value of multidisciplinary care and its current state in cardiovascular disease and prostate cancer.

Maria Lopes, MD, MS, elucidates the potential for quality measures and coverage policies to incorporate cardiovascular disease (CVD) and improve outcomes in prostate cancer.

Experts share insight on the need for clinical or real-world evidence to further solidify cardiovascular disease risk as an actionable factor in prostate cancer.

Expert perspectives on factors that inform prostate cancer therapy selection while keeping cardiovascular disease in mind.

Continuing their discussion on cost of care in prostate cancer, experts reflect on how cardiovascular disease impacts risk-bearing practices and alternative payment models.

Shared insight on the impact that cardiovascular disease has on cost of care in prostate cancer.

Experts consider available professional society guidelines on prostate cancer and cardiovascular disease management.

A brief review of factors that may put patients with prostate cancer at increased risk for developing cardiovascular disease.

Reasons for pursuing genomic profiling among patients with advanced bladder, renal, and prostate cancers included guiding treatment and improving treatment response, in which age and education level were found to significantly influence shared decision-making.

Focusing on available agents in prostate cancer, experts consider how androgen deprivation therapy impacts risk of cardiovascular disease.

A comprehensive review of the therapeutic classes available for patients with prostate cancer.

Shared insight on the correlation between prostate cancer and cardiovascular disease, with a focus on the attributes that increase a patient’s risk.

Experts in gynecologic oncology and genitourinary oncology discuss the current state of PARP inhibitors in prostate and ovarian cancers.

Bayer and Orion corporation today announced the upcoming expansion of the global clinical development program for darolutamide (Nubeqa), an oral androgen receptor inhibitor for patients with prostate cancer.

Results from the phase 3 PRECISE trial showed that MRI with targeted biopsies matched or exceeded the accuracy of the current standard for detecting clinically significant prostate cancer.

Shortening a traditional 45-day course of radiation therapy to 5 days of stereotactic body radiotherapy for patients with advanced, high-risk prostate cancer is safe and effective, a study from UCLA Jonsson Comprehensive Cancer Center found.

A recent study from the University of Texas MD Anderson Cancer Center found that men with localized prostate cancer on active surveillance might benefit from following a Mediterranean-style diet.

Magnetic resonance imaging (MRI) is often used in the diagnosis and management of prostate cancer, but the method frequently underestimates tumor size, a study in the Journal of Urology shows.